Novel mTORC1 Inhibitors Kill Glioblastoma Stem Cells

Area of Science:

• Neuro-oncology
• Pharmacology
• Molecular Biology

Background:

• Glioblastoma (GBM) is an aggressive brain tumor with poor prognosis.
• GBM stem cells (GBMSC) resist standard therapy (temozolomide) contributing to treatment failure.
• Mammalian target of rapamycin Complex 1 (mTORC1) activity is altered in GBMSC and is a potential therapeutic target.

Purpose of the Study:

• To evaluate novel piperazine-based mTORC1 inhibitors for glioblastoma treatment.
• To assess the efficacy of these inhibitors alone and in combination with temozolomide.
• To investigate their effect on IDH1-mutated GBM stem cells.

Main Methods:

• Biophysical assays (biolayer interferometry, field-effect biosensing) to measure drug-target binding.
• In vitro testing of piperazine inhibitors' killing potency against GBMSC.
• Combination therapy studies with temozolomide and specific piperazines (meclizine, flunarizine).
• Investigation of drug effects on IDH1-mutated GBMSC.

Main Results:

• Piperazine derivatives demonstrated strong binding to mTORC1 with a clear structure-activity relationship.
• The tightest-binding piperazines effectively killed GBMSC.
• Combination therapy of temozolomide with meclizine or flunarizine significantly enhanced GBMSC death compared to temozolomide alone.
• Meclizine induced synthetic lethality in IDH1-mutated GBMSC, increasing their sensitivity to temozolomide.

Conclusions:

• Novel piperazine-based mTORC1 inhibitors are potent GBMSC killers.
• Co-administration of meclizine or flunarizine with temozolomide represents a promising therapeutic strategy for GBM.
• This combination therapy, particularly with meclizine, shows potential for treating IDH1-mutant GBM through synthetic lethality.